Racial disparities in overall survival among renal cell carcinoma patients with young age and small tumors

Kendra Schwartz1,2, Julie J. Ruterbusch2,3, Joanne S. Colt4, David C. Miller5, Wong-Ho Chow6 & Mark P. Purdue4

1Department of Family Medicine and Public Health Sciences, Wayne State University School of Medicine, Detroit, Michigan
2Population Studies and Disparities Research Program, Karmanos Cancer Institute, Detroit, Michigan
3Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan
4Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland
5Department of Urology, University of Michigan Medicine School, Ann Arbor, Michigan
6Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Keywords
Age, race, renal cell carcinoma, survival, tumor size

Abstract
We examined the overall survival of a population-based cohort of black and white patients with renal cell carcinoma (RCC) to better understand the paradox of poorer RCC survival despite more frequent diagnosis at lower stage among blacks. Renal cell carcinoma patients (699 white, 252 black) diagnosed between 2002 and 2007 in metropolitan Detroit were followed for vital status in the Detroit Surveillance, Epidemiology and End Results (SEER) registry. Hazard ratios (HR) of death for black versus white race and 95% confidence intervals (CIs) were calculated using Cox proportional hazard models stratified by demographic and prognostic factors, and in models successively adjusted for clinical factors, comorbidities, and socioeconomic factors. Mean follow-up time was 88.4 months for white patients and 89.6 months for black patients (P = 0.49), with 202 white deaths and 89 black deaths (P = 0.06). While black race was weakly associated with poorer overall survival (P = 0.053), black patients <65 years at diagnosis or with tumors ≤4 cm in size had significantly poorer survival than their white counterparts (HR = 1.46, 95% CI 1.06–2.01 and HR = 2.15, 95% CI 1.51–3.06, respectively). The racial disparities within these two subgroups were minimally affected by adjustment for clinical/treatment factors (HR = 1.49, 95% CI 1.01–2.19 and HR = 1.95, 95% CI 1.27–2.99), but were substantially reduced when renal-relevant comorbidities were added (HR = 1.30, 95% CI 0.89–1.91 and HR = 1.76, 95% CI 1.16–2.66). After further adjustment for socioeconomic factors, the survival disparities were essentially null (HR = 1.14, 95% CI 0.71–1.85 and HR = 1.15, 95% CI 0.67–1.98). In this population-based sample of RCC patients, younger black patients and those with small tumors had poorer overall survival than whites. The disparity was explained primarily by racial differences in renal-relevant comorbidities, particularly chronic renal failure, and socioeconomic deprivation. Future research should focus on younger patients and those with smaller tumors to better understand how these factors may contribute to the survival disparity.

Introduction
The incidence of renal cell carcinoma (RCC) doubled between 1975 and 2010, from 7.08 to 14.7 per 100,000 [1], driven in large part by localized tumors [2–5], resulting in a stage shift from 43% to 57% Stage 1 tumors between 1993 and 2004 in the National Cancer Database [5]. This increase in smaller tumors, especially those ≤4 cm, is thought
to be due to increased detection of incidental tumors upon imaging for abdominal complaints [2, 6]. Retrospective studies of incidentally discovered tumors indicate that they are indeed smaller and associated with improved survival compared to symptomatic RCC tumors [7–9].

The increase in RCC incidence is greater among blacks than other racial groups, owing in large part to an increase in localized tumors [3, 10–12]. Despite the fact that black RCC patients are more likely to be diagnosed with early-stage cancer than their white counterparts, black patients have consistently been reported to have poorer overall survival [3, 10, 13, 14]. Investigations of the cause for this survival disparity are rare. A population-based SEER-Medicare study of patients 65 years and older observed the disparity to be largely attributable to less use of surgical treatment among blacks compared with whites [13].

Because the SEER-Medicare study included only elderly patients who were diagnosed between 1986 and 1999, we examined survival patterns among black and white cases of all ages enrolled in the Kidney Cancer Study (KCS), a large case-control study of RCC cases diagnosed between 2002 and 2007. With this resource, we were able to investigate potential influences on overall survival using variables available in SEER, as well as comorbidity and socioeconomic status information from the cases, which is not available in SEER or SEER-Medicare databases. Additionally, the KCS collected data related to the symptoms at diagnosis, which has been reported by others as being associated with overall survival of RCC patients [15].

Methods

Study overview

The KCS is a population-based case-control study conducted in the metropolitan areas of Detroit, Michigan (Wayne, Oakland, and Macomb Counties) and Chicago, Illinois (Cook County) from 2002 through 2007. Eligible cases were white and black men and women aged 20 to 79 years, with a diagnosis of RCC between 1 February 2002 and 31 July 2007 in Detroit, or 1 January 2003 through 31 December 2003 in Chicago (Hispanic ethnicity was not an inclusion/exclusion criterion). In Detroit, potential cases were identified through the Metropolitan Detroit Cancer Surveillance System, an NCI Surveillance, Epidemiology, and End Results (SEER) program member. This report contains information only for the Detroit cases because SEER data were available to augment clinical information necessary for the analyses and provided vital status information. Cases were followed for vital status through 31 December 2012.

A detailed description of data collection methods was published previously [16]. Briefly, participants were recruited by first sending an introductory letter, then by telephone, to participate in a 90-min epidemiological interview, as well as the optional provision of saliva and blood samples. Participants were offered compensation for their time and effort. At the time of interview, cases were also asked to provide their consent for us to access and review relevant medical records, pathology reports, and tissue samples. If the participant consented to medical record release and tissue samples, a request was sent to the facility and those records/samples were mailed to the study office. The study was approved by the Institutional Review Boards at all participating institutions.

We enrolled 1018 cases from among the 1603 Detroit area patients identified as potentially eligible for this study. This analysis is restricted to Detroit cases that consented to both the interview and medical record review (N = 951). The proportions of black and white cases (24%, 66%) are similar to the racial composition of the metropolitan Detroit tri-county area from which the sample was obtained, which was 25.0% black and 68.9% white in 2000 (U.S. Census) [17].

Study variables

Demographic and clinical characteristics were obtained from the following sources: (1) participant interview, (2) review of medical records related to the RCC diagnosis, and (3) SEER tumor registry data. From the participant interview, we obtained highest level of educational attainment and detailed medical history regarding comorbidities relevant to renal function, including whether they had ever been told by a doctor that they had diabetes, hypertension, or chronic renal/kidney failure 2 or more years prior to interview. The medical records provided information on presenting signs and symptoms, RCC clinical and pathological characteristics (AJCC stage and Fuhrman grade), and treatment(s). The SEER program provided cancer-specific information, including tumor size, histology, and vital status.

Using these data, we classified each case into one of three symptom categories at presentation: asymptomatic, local symptoms (e.g., flank or abdominal pain, hematuria), or systemic symptoms (e.g., weight loss, night sweats), similar to previous publications that have demonstrated an association between extent of symptoms at diagnosis and long-term survival among patients with RCC [6, 7]. For analytic purposes, we defined four categories of surgical treatments: (1) no surgery, (2) open radical nephrectomy (ORN), (3) laparoscopic radical nephrectomy (LRN), and (4) nephron-sparing surgery (NSS; includes both partial
Table 1. Comparison of demographic and clinical characteristics of black and white study participants, Detroit Surveillance, Epidemiology and End Results renal cell carcinoma cases diagnosed between 2002 and 2007.

|                       | White ($n = 699$) | Black ($n = 252$) | $P$ value* |
|-----------------------|-------------------|-------------------|------------|
| **Sex**               |                   |                   |            |
| Male                  | 396 (0.57)        | 148 (0.59)        | 0.57       |
| Female                | 303 (0.43)        | 104 (0.41)        |            |
| **Age at diagnosis**  |                   |                   |            |
| <65 years             | 461 (0.66)        | 182 (0.72)        | 0.07       |
| ≥65 years             | 238 (0.34)        | 70 (0.28)         |            |
| Mean (SD)             | 58.8 (11.6)       | 57.6 (10.5)       | 0.15       |
| **Tumor size (cm)**   |                   |                   |            |
| ≤4 cm                 | 348 (0.50)        | 135 (0.54)        | 0.63       |
| 4–7 cm                | 190 (0.27)        | 66 (0.26)         |            |
| >7 cm                 | 147 (0.21)        | 48 (0.19)         |            |
| Unknown               | 14 (0.02)         | 3 (0.01)          |            |
| Mean (SD)             | 5.3 (4.9)         | 4.9 (3.2)         | 0.12       |
| **AJCC stage**        |                   |                   |            |
| I                     | 452 (0.65)        | 182 (0.72)        | 0.03       |
| II                    | 75 (0.11)         | 29 (0.12)         |            |
| III or IV             | 139 (0.20)        | 32 (0.13)         |            |
| Missing               | 33 (0.05)         | 9 (0.04)          |            |
| **Histology**         |                   |                   |            |
| Clear cell            | 533 (0.76)        | 148 (0.59)        | <0.01      |
| Papillary             | 76 (0.11)         | 65 (0.26)         |            |
| Chromophobe           | 42 (0.06)         | 17 (0.07)         |            |
| Cystic                | 36 (0.05)         | 16 (0.06)         |            |
| Other                 | 12 (0.02)         | 6 (0.02)          |            |
| **Fuhrman grade**     |                   |                   |            |
| I                     | 80 (0.11)         | 21 (0.08)         | 0.35       |
| II                    | 311 (0.44)        | 117 (0.46)        |            |
| III and IV            | 204 (0.29)        | 79 (0.31)         |            |
| Missing               | 104 (0.15)        | 35 (0.14)         |            |
| **Surgical treatment**|                   |                   |            |
| None                  | 26 (0.04)         | 10 (0.04)         | 0.54       |
| Open radical nephrectomy | 323 (0.46)    | 104 (0.41)        |            |
| Laparoscopic radical nephrectomy | 220 (0.31) | 83 (0.33)        |            |
| Nephron-sparing surgery | 130 (0.19)   | 55 (0.22)         |            |
| **Symptomatology**   |                   |                   |            |
| Asymptomatic          | 275 (0.39)        | 113 (0.45)        | 0.01       |
| Local                 | 261 (0.37)        | 71 (0.28)         |            |
| Systemic              | 107 (0.15)        | 51 (0.20)         |            |
| Unknown               | 56 (0.08)         | 17 (0.07)         |            |
| **History of renal-relevant comorbidities** |           |                   |            |
| None                  | 297 (0.42)        | 60 (0.24)         | <0.01      |
| Hypertension only     | 288 (0.41)        | 115 (0.46)        |            |
| Diabetes only         | 26 (0.04)         | 6 (0.02)          |            |
| Hypertension and diabetes (without renal failure) | 78 (0.11) | 39 (0.15)        |            |
| Chronic renal failure | 10 (0.01)         | 32 (0.13)         |            |
| **Deprivation index\textsuperscript{1}** |           |                   |            |
| Q1 (lowest)           | 204 (0.29)        | 15 (0.06)         | <0.01      |
| Q2                    | 187 (0.27)        | 21 (0.08)         |            |
| Q3                    | 216 (0.31)        | 15 (0.06)         |            |
| Q4                    | 72 (0.10)         | 98 (0.39)         |            |
| Q5 (highest)          | 20 (0.03)         | 103 (0.41)        |            |

(Continued)
nephrectomy and energy-ablative therapies performed by any approach).

Individual-level educational attainment was analyzed as less than high school, high school graduate or equivalent, some college, and completion of college and/or a professional degree. A contextual measure of economic deprivation, termed deprivation index (DI), which captures multiple dimensions of the economic and social conditions of neighborhoods including unemployment, poverty, overcrowding, and telephone and automobile availability have been used previously in cancer studies [18–20]. Our DI was created using census-tract-level data from the 2000 U.S. Census and the case address at diagnosis. The DI ranges from 0 to 1, where 0 indicates no deprivation (i.e., no unemployment; all households with phone, automobile, and more than one room per person; no individuals living below poverty level) and 1 indicates maximum deprivation. For the purpose of our analysis, DI was categorized into quintiles based on the distribution of deprivation in the metropolitan Detroit area: (Q1 < 0.022, 0.022 < Q2 < 0.035, 0.035 < Q3 < 0.056, 0.056 < Q4 < 0.142, 0.142 < Q5 < 0.531).

Statistical analyses
We used chi-square tests to assess racial differences in demographic and cancer-specific characteristics of the RCC cases, as well as differences in their clinical presentation, diagnosis, and treatment. Overall hazard of death for blacks compared to white was estimated, with stratification by each demographic and cancer-related variable. Cox proportional hazards regression models were then stratified by those variables found to be significant in the bivariate model as well as DI (Q1–Q2 vs. Q3–Q5) and a history of renal-relevant comorbidities (yes/no). The hazard of death associated with black race was evaluated in progressive models adjusted first for the effects of sex, age at diagnosis, tumor size, stage, histology, Fuhrman grade, symptoms at diagnosis, and nephron-sparing surgery, and then additionally adjusted for history of renal-relevant comorbidities, and finally adjusted for deprivation index and education. Survival curves were generated using the Kaplan–Meier method to illustrate black–white differences.

All statistical testing was two sided and performed at the 5% significance level (SAS v9.2, SAS Institute, Cary, NC).

Results
The mean follow-up time was 88.4 months for white patients (n = 699) and 89.6 months for black patients (n = 252) (P = 0.49). Black patients were more likely than white patients to be of lower AJCC stage (P = 0.03), to have RCC of papillary histology (P < 0.01), to report either no symptoms or systemic symptoms (P = 0.01), to live in a deprived socioeconomic neighborhood (P < 0.01), to report fewer years of education (P < 0.01), and to report a history of renal-relevant comorbidities (P < 0.01), with the largest difference seen in the report of chronic renal failure (13% vs. 1%; Table 1).

In Table 2, hazard of death for black race was compared to white race, overall and stratified by the variables in Table 1. Overall, black patients had slightly poorer survival
RCC Racial Survival Disparity

Table 2. Univariate hazard of death for black race\(^1\) stratified by prognostic and demographic variables, Detroit Surveillance, Epidemiology and End Results renal cell carcinoma cases diagnosed between 2002 and 2007.

|                         | Black race |                |
|-------------------------|------------|----------------|
|                         | HR (95% CI)| P value        |
| Overall                 | 1.28 (1.00–1.64) | 0.053 |
| By sex                  |            |                |
| Male                    | 1.18 (0.86–1.62) | 0.309 |
| Female                  | 1.43 (0.96–2.14) | 0.079 |
| By age at diagnosis     |            |                |
| <65 years               | 1.46 (1.06–2.01) | 0.020 |
| 65+ years               | 1.12 (0.75–1.68) | 0.588 |
| By tumor size (cm)      |            |                |
| ≤4 cm                   | 2.15 (1.51–3.06) | <0.001 |
| >4 cm                   | 0.81 (0.56–1.19) | 0.284 |
| By AJCC stage           |            |                |
| I                       | 1.67 (1.20–2.33) | 0.002 |
| II                      | 0.55 (0.23–1.32) | 0.178 |
| III                     | 1.73 (0.83–3.60) | 0.145 |
| IV                      | 0.95 (0.51–1.78) | 0.880 |
| By histology            |            |                |
| Clear cell              | 1.34 (0.98–1.83) | 0.069 |
| Papillary               | 1.00 (0.54–1.82) | 0.987 |
| Chromophobe             | 1.05 (0.33–3.32) | 0.939 |
| Cystic                  | 2.18 (0.84–5.65) | 0.110 |
| Other                   | 0.89 (0.27–3.00) | 0.856 |
| By Fuhrman grade        |            |                |
| I and II                | 1.37 (0.94–1.99) | 0.104 |
| III and IV              | 1.30 (0.87–1.93) | 0.199 |
| By surgical treatment   |            |                |
| None                    | 1.19 (0.50–2.86) | 0.693 |
| Open radical nephrectomy| 1.33 (0.94–1.87) | 0.108 |
| Laparoscopic radical nephrectomy | 1.49 (0.91–2.44) | 0.116 |
| Nephron-sparing surgery | 1.13 (0.57–2.24) | 0.723 |
| By symptomatology       |            |                |
| Asymptomatic            | 1.37 (0.92–2.06) | 0.126 |
| Local                   | 0.98 (0.61–1.57) | 0.915 |
| Systemic                | 1.09 (0.65–1.83) | 0.736 |
| By history of renal-relevant comorbidities |            |                |
| None                    | 1.38 (0.83–2.29) | 0.212 |
| Hypertension only       | 1.02 (0.68–1.53) | 0.919 |
| Diabetes only           | 0.78 (0.17–3.59) | 0.748 |
| Hypertension and diabetes (without chronic renal failure) | 0.85 (0.46–1.58) | 0.609 |
| Chronic renal failure   | 1.25 (0.50–3.13) | 0.642 |
| By deprivation index\(^2\) |            |                |
| Q1 (lowest)             | 1.52 (0.61–3.82) | 0.373 |
| Q2                      | 0.74 (0.30–1.85) | 0.524 |
| Q3                      | 0.67 (0.21–2.13) | 0.494 |
| Q4                      | 0.94 (0.57–1.57) | 0.816 |
| Q5 (highest)            | 1.46 (0.58–3.68) | 0.429 |
| By education            |            |                |
| Less than high school   | 1.27 (0.75–2.15) | 0.378 |
| High school graduate    | 1.10 (0.70–1.74) | 0.673 |
| 1–3 years of college    | 1.41 (0.90–2.22) | 0.135 |
| College graduate        | 0.90 (0.40–2.02) | 0.807 |

\(\text{HR}\) = hazard ratio; \(\text{CI}\) = confidence interval; \(\text{AJCC}\) = American Joint Committee on Cancer.

\(^{1}\)Compared to white race.

\(^{2}\)See Table 1 footnote for definition.

Figure 1. Racial differences in overall survival by age at diagnosis, Detroit Surveillance, Epidemiology and End Results renal cell carcinoma cases diagnosed between 2002 and 2007. (A) Less than 65 years and (B) 65 years or older at diagnosis.

than white patients (HR = 1.28, 95% CI 1.00–1.65). For black patients who were <65 years old at diagnosis (HR = 1.46, 95% CI 1.06, 2.01), had a tumor size of 4 cm or less (HR = 2.15, 95% CI 1.51, 3.06), or were diagnosed at AJCC stage I (HR = 1.67, 95% CI 1.20, 2.33), the survival disparity was substantial. Kaplan–Meier plots and Cox regression models were stratified by tumor size (<4 cm, >4 cm) and age (<65 years, ≥65 years).

The unadjusted survival disparities for younger age and smaller tumor size are shown in Figures 1 and 2, respectively. There was better survival among young white patients compared to black patients (\(P = 0.025\)), but survival was similar for the races among patients 65 years and older (\(P = 0.534\)). White patients with smaller tumors had better overall survival than black patients (\(P < 0.0001\)), but no significant racial difference was seen for larger tumors (\(P = 0.265\)).
Table 3 includes the results of successive multivariable modeling for both younger patients and those with smaller tumors. The hazard ratios for black race among patients under 65 years of age (HR = 1.49, 95% CI 1.01–2.19) or with tumors 4 cm or less in size (HR = 1.95, 95% CI 1.27–2.99) were minimally affected by the addition of clinical/treatment factors into the models. However, the HRs were weakened when comorbidities were added as covariates (HR = 1.30, 95% CI 0.89–1.91 and HR = 1.76, 95% CI 1.16–2.66, respectively), and approached the null with additional adjustment for socioeconomic factors (HR = 1.14, 95% CI 0.71–1.85 and HR = 1.15, 95% CI 0.67–1.98, respectively). The pattern for low AJCC stage (I and II) is similar to that seen for smaller tumors, as would be expected because tumor size is a component of the RCC staging criteria. The strata of deprivation index and renal-relevant comorbidities showed insignificant HRs throughout the sequential models.

We tested the proportional hazards assumption in the multivariate models by adding an interaction term with race and follow-up time to the final models. This interaction term was not significant for the overall model or for the stratified models.

The distribution of the DI and renal-relevant comorbidities by race was evaluated to determine if the pattern differed for the age and tumor size subgroups. The racial distributions within the age and tumor size groups were very similar; black patients were more likely to live in areas of high economic deprivation and reported a higher number of renal-relevant comorbidities in the same proportion regardless of age or tumor size (data not shown).

To be confident that nonsurgically treated patients (N = 36) were not influencing the results, we repeated the multivariable analyses after excluding them from the models and the results were nearly identical to those provided in Tables 2 and 3 (data not shown).

**Discussion**

In this population-based sample of RCC patients, we found that overall survival for all black patients was slightly poorer than their white counterparts. However, black patients <65 years old at diagnosis and those presenting with small tumors had significantly poorer overall survival than white patients. The racial disparity in survival within these two subgroups was no longer apparent after model adjustment for renal-relevant comorbidities and socioeconomic indicators. However, adjusting for presenting symptoms and treatment type had no effect on survival.

Our results suggest that renal-relevant comorbidities (hypertension, diabetes, and chronic renal failure) are major contributors to the poorer overall survival among young black patients and black patients with smaller tumors. Moreover, fewer blacks reported having no renal-relevant comorbidities, and chronic renal failure was reported significantly more often by black patients (13% vs. 1%). Berndt et al. [13], using the SEER-Medicare database, also looked at black/white RCC survival disparities among patients 65 years and older, a group for which we found no statistically significant survival disparity. They found that lack of nephrectomy accounted for much of the poorer survival among black Medicare patients. Furthermore, among patients undergoing nephrectomy, blacks had worse survival; however, adjustment for end-stage renal disease reduced the racial disparity. Hypertension-related end-stage renal disease is more common and typically more severe among blacks compared to whites [21], and appears to be mainly explained by the presence of APOL1 genetic variants that are strongly
associated with risk of selected nonmalignant kidney diseases in populations of African ancestry [22]. Additionally, chronic renal failure appears to be a stronger risk factor for RCC among blacks than whites, possibly due to pathologic changes related to loss of renal function [23, 24]. These same pathological changes also may lead to poorer survival, particularly among black RCC patients.

Our finding that socioeconomic factors, both neighborhood deprivation and individual education level, was important in attenuating the racial survival disparity among younger patients and in patients with smaller tumors has not been previously reported. The black patients in our population were of significantly lower socioeconomic status than the white patients, with over 80% of blacks living in the most deprived neighborhoods, regardless of their age or tumor size. It has been shown that socioeconomic status differentially influences patterns of morbidity and mortality by race, with black patients more likely to be negatively affected than whites with similar socioeconomic profiles [25, 26]. Additionally, racial residential segregation is thought to represent a fundamental cause of racial disparities in health [27], and metropolitan Detroit is often cited as one of the most racially segregated urban areas in the United States [28]. Lower socioeconomic status can result in lower access to care, which can affect survival. Although both black and white patients in our study had similar rates of surgery and nephron-sparing procedures, there may be nonmeasured access factors, such as treatment delays or surgical complications, which may be affecting survival. Other aspects of low socioeconomic status, such as stress, lack of social support systems, and environmental exposures, could not be evaluated in this study and should be the focus of future investigations of racial disparities in RCC survival.

Chow et al. [14], using national SEER data, reported that black RCC patients had poorer 5-year relative survival than whites regardless of age, sex, tumor stage or size, histological subtype, or surgical treatment. However, information on comorbidities and socioeconomic deprivation are not available within the SEER database, unlike our study. In contrast, we found a survival disparity between black and white patients, particularly among younger patients and those with smaller tumors, and these racial disparities were largely explained by more prevalent comorbidities and social deprivation among blacks. Our observations underscore the importance of socioeconomic contextual environment in influencing RCC survival. Yet it is unclear why younger black patients and those with smaller tumors appear to be more affected by deprivation compared to whites than older black patients and those with larger tumors. One important factor related to age may be the availability of Medicare insurance at age 65 years and older.

Petard et al. [15] demonstrated that symptomatology (categorized as asymptomatic, renal specific symptoms and systemic symptoms) was predictive of overall survival independent of AJCC stage and Fuhrman grade, and was a better predictor than ECOG functional status. Within our population, black patients had a higher prevalence of systemic symptoms, yet adjusting for symptomatology did little to attenuate the elevated hazard ratios seen.

This population-based study provided a unique opportunity to investigate racial differences in RCC survival among both young and elderly patients, with adjustment

### Table 3. Relative hazard of death for black race compared to white race, sequentially adjusted for prognostic variables, Detroit Surveillance, Epidemiology and End Results renal cell carcinoma cases diagnosed between 2002 and 2007.

|                      | Unadjusted | Model 1 | Model 2 | Model 3 |
|----------------------|------------|---------|---------|---------|
|                      | HR (95% CI)| HR (95% CI) | HR (95% CI) | HR (95% CI) |
| Overall              | 1.28 (1.00–1.64) | 1.32 (0.98–1.79) | 1.17 (0.87–1.57) | 0.93 (0.65–1.35) |
| Age at diagnosis     |            |         |         |         |
| <65                  | 1.46 (1.06–2.01) | 1.49 (1.01–2.19) | 1.30 (0.89–1.91) | 1.14 (0.71–1.85) |
| ≥65                  | 1.12 (0.75–1.68) | 1.04 (0.64–1.68) | 0.86 (0.53–1.38) | 0.64 (0.36–1.14) |
| Tumor size           |            |         |         |         |
| ≤4 cm                | 2.15 (1.51–3.06) | 1.95 (1.27–2.99) | 1.76 (1.16–2.66) | 1.15 (0.67–1.98) |
| >4 cm                | 0.81 (0.56–1.19) | 0.93 (0.59–1.47) | 0.80 (0.51–1.26) | 0.74 (0.44–1.27) |
| AJCC stage           |            |         |         |         |
| I                    | 1.67 (1.20–2.33) | 1.67 (1.17–2.40) | 1.33 (0.90–1.94) | 0.91 (0.56–1.47) |
| II–IV                | 1.10 (0.73–1.67) | 1.00 (0.61–1.62) | 0.95 (0.58–1.54) | 0.88 (0.49–1.60) |

Model 1: Adjusted for sex, age at diagnosis, tumor size, AJCC stage, histology, Fuhrman grade, symptomatology, nephron-sparing surgery.
Model 2: Adjusted for all model 1 variables plus history of diabetes, hypertension, and chronic renal failure.
Model 3: Adjusted for all model 2 variables plus education level and deprivation index.

1For stratified analyses, models are not adjusted for that strata variable.
for both prognostic and socioeconomic factors. However, several limitations must be acknowledged. The renal-relevant comorbidities used in this study were based on self-report and were not verified. Although it is likely that most patients know their diagnosis, especially of more common diseases like hypertension and diabetes, it is unclear how knowledgeable they would be of chronic renal failure unless they were receiving dialysis. In fact, approximately 70% of those reporting chronic renal failure also reported dialysis, regardless of tumor size. The study sample size also may be considered low, especially for black cases, resulting in wider confidence intervals as well as the possibility of false positive findings. Finally, we were able to interview only those RCC cases that had not died prior to contact. The most aggressive types of RCC are thus underrepresented in this sample.

In conclusion, our findings suggest that in metropolitan Detroit, the poorer survival experienced by black RCC patients compared to white patients, despite being diagnosed at a more favorable stage of disease, is mainly attributable to racial differences in comorbidities, particularly chronic renal failure, and factors associated with low socioeconomic status. These factors particularly affect younger black patients and those with smaller tumors; however, the reasons for this remain unclear. The associations are likely to be interrelated and complex and deserve further research.

Conflicts of Interest

None declared.

References

1. Howlender, N., A. M. Noone, M. Krapcho, J. Garshell, N. Neyman, S. F. Altekruse, et. al. 2013. SEER Cancer Statistics Review, 1975–2010, National Cancer Institute, Bethesda MD, http://seer.cancer.gov/csr/1975_2010, based on November 2012 SEER data submission, posted to SEER web site, April 2013.
2. Chow, W., S. Devesa, J. Warren, and J. Fraumeni. 2008. Rising incidence of renal cell cancer in the United States. JAMA 281:1628–1631.
3. Vaishampayan, U., H. Do, M. Hussain, and K. Schwartz. 2003. Racial disparity in incidence patterns and outcomes of kidney cancer. Urology 62:1012–1017.
4. Hollingsworth, J., D. Miller, S. Daignault, and B. Hollenbeck. 2006. Rising incidence of small renal masses: a need to reassess treatment effect. J. Natl Cancer Inst. 98:1331–1334.
5. Kane, C., K. Mallin, J. Ritchey, M. Cooperberg, and P. Carroll. 2008. Renal cell cancer stage migration. Cancer 113:78–83.
6. Jayson, M., and H. Sanders. 1998. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51:203–205.
7. Patard, J., A. Rodriguez, N. Rioux-Leclercq, F. Guille, and B. Lobel. 2002. Prognostic significance of the mode of detection in renal tumours. BJU Int. 90:358–363.
8. Luciani, L., R. Cestari, and C. Tallarigo. 2000. Incidental renal cell carcinoma age and stage characterization and clinical implications: study of 1092 patients (1982–1997). Urology 56:58–62.
9. Lee, C., J. Katz, P. Fearn, and P. Russo. 2002. Mode of presentation of renal cell carcinoma provides prognostic information. Urol. Oncol. 7:135–140.
10. Stafford, H., S. Saltzstein, S. Shimasaki, C. Sanders, T. Downs, and G. Sadler. 2008. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J. Urol. 179:1704–1708.
11. Lipworth, L., J. McLaughlin, R. Tarone, and W. Blot. 2011. Renal cancer paradox: Higher incidence but not higher mortality among African Americans. Eur. J. Cancer Prev. 20:331–333.
12. Chow, W., and S. Devesa. 2008. Contemporary renal cell cancer epidemiology. Cancer J. 14:288–301.
13. Berndt, S. I., H. B. Carter, M. P. Schoenberg, and C. J. Newschaffer. 2007. Disparities in treatment and outcome for renal cell cancer among older black and white patients. J. Clin. Oncol. 25:3589–3595.
14. Chow, W. H., B. Shuch, W. M. Linehan, and S. S. Devesa. 2013. Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer 119:388–394.
15. Patard, J. J., E. Leray, L. Cindolo, V. Ficarra, A. De La Taille, J. Tostain, et. al. 2004. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J. Urol. 172:858–862.
16. Miller, D. C., J. Ruterbusch, J. S. Colt, F. G. Davis, W. M. Linehan, W. H. Chow, et. al. 2010. Contemporary clinical epidemiology of renal cell carcinoma: insight from a population-based case-control study. J. Urol. 184:2254–2258.
17. U.S. Census Bureau. Census 2000, generated by J. Ruterbusch; using American FactFinder. Available at http://factfinder2.census.gov (accessed on 19 March 2015).
18. Klassen, A. C., F. C. Curriero, J. H. Hong, C. Williams, M. Kulldorff, H. I. Meissner, et. al. 2004. The role of area-level influences on prostate cancer grade and stage at diagnosis. Prev. Med. 39:441–448.
19. Zeigler-Johnson, C. M., A. Tierney, T. R. Rebbeck, and A. Rundle. 2011. Prostate cancer severity associations with neighborhood deprivation. Prostate Cancer 2011:846263.
20. Simon, M. S., L. Lamerato, R. Krajenta, J. C. Booza, J. J. Rutterbusch, S. Kunz, et. al. 2012. Racial differences in the use of adjuvant chemotherapy for breast cancer.

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
in a large urban integrated health system. Int. J. Breast Cancer 2012:453985.
21. Appel, L. J., J. T. Wright Jr., T. Greene, L. Y. Agodoa, B. C. Astor, G. L. Bakris, et. al. 2010. Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med. 363:918–929.
22. Freedman, B. L., J. B. Kopp, C. D. Langefeld, G. Genovese, D. J. Friedman, G. W. Nelson, et. al. 2010. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J. Am. Soc. Nephrol. 21:1422–1426.
23. Hall, E. C., D. L. Segev, and E. A. Engels. 2013. Racial/ethnic differences in cancer risk after kidney transplantation. Am. J. Transplant. 13:714–720.
24. Hofmann, J. N., K. Schwartz, W. H. Chow, J. J. Ruterbusch, B. M. Shuch, S. Karami, et. al. 2013. The association between chronic renal failure and renal cell carcinoma may differ between black and white Americans. Cancer Causes Control 24:167–174.
25. Farmer, M. M., and K. F. Ferraro. 2005. Are racial disparities in health conditional on socioeconomic status? Soc. Sci. Med. 60:191–204.
26. Franks, P., P. Muennig, E. Lubetkin, and H. Jia. 2006. The burden of disease associated with being African-American in the United States and the contribution of socio-economic status. Soc. Sci. Med. 62:2469–2478.
27. Williams, D. R., and C. Collins. 2001. Racial residential segregation: a fundamental cause of racial disparities in health. Public Health Rep. 116:404–416.
28. Logan, J. R. 2013. The persistence of segregation in the 21st century metropolis. City Commun. 12:160–168.